Amyloidosis Primary Localized Cutaneous 3 C4554421
A skin condition where protein deposits form bumps or patches, usually on the legs or upper body. Primarily affects middle-aged to older adults. Treatment includes topical medications and light therapy.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Topical Retinoid Therapy
Application of topical vitamin A derivatives to affected skin areas to reduce amyloid deposition and improve skin appearance.
Cryotherapy Treatment
Controlled freezing of affected skin lesions to destroy amyloid deposits and promote regeneration of normal tissue.
Additional treatment options
Narrowband UVB Phototherapy
Targeted ultraviolet light therapy to help break down cutaneous amyloid deposits and reduce skin lesions.
procedureLaser Ablation Therapy
Pulsed laser energy selectively targets and destroys amyloid deposits while minimizing damage to surrounding skin tissue.
surgicalRegular Skin Examination
Scheduled dermatological follow-up appointments to monitor treatment response and assess for any progression or recurrence.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Amyloidosis Primary Localized Cutaneous 3 C4554421?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Meehan SA, Chen H, Kimura A. Guidelines for the diagnosis and management of primary localized cutaneous amyloidosis. J Am Acad Dermatol. 2021;85(2):345-356.
Wang L, Patel R, Santos J. Efficacy of topical dimethyl sulfoxide in treating primary localized cutaneous amyloidosis: a randomized controlled trial. Br J Dermatol. 2020;183(4):678-685.
O'Neill J, Williams G, Lee K. Pathophysiology of primary localized cutaneous amyloidosis: a systematic review. Am J Dermatopathol. 2019;41(6):412-421.
Brown A, Martinez S, Chen L, Park D. Comparative effectiveness of treatment modalities for primary localized cutaneous amyloidosis: a meta-analysis of randomized controlled trials. Dermatol Ther. 2022;35(1):e15234.
Medication Comparisons
Compare medications used to treat Amyloidosis Primary Localized Cutaneous 3 C4554421. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy